Please provide your email address to receive an email when new articles are posted on . A once-weekly basal insulin provided noninferior HbA1c reductions compared with once-daily insulins in adults ...
COMBINE 3 phase 3a trial successfully completed with once-weekly IcoSema demonstrating non-inferior reduction in HbA1c versus daily basal-bolus treatment (insulin glargine U100 and insulin aspart) in ...
According to CRL, more information regarding the manufacturing process and the type 1 diabetes indication is needed before the review can be completed. The Food and Drug Administration (FDA) has ...
Insulin efsitora alfa (efsitora) is a new basal insulin designed for once-weekly administration. Data on safety and efficacy have been limited to small, phase 1 or phase 2 trials. We conducted a ...
Please provide your email address to receive an email when new articles are posted on . Of 20 hospitals providing insulin algorithms, 60% stated which patients should initiate basal or nutritional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results